Regenxbio annual ebitda
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Regenxbio EBITDA Growth & History (RGNX)
Regenxbio's calculated EBITDA was −$145.6M for fiscal 2025.
View full Regenxbio company overviewRegenxbio annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$145.6M | $71.5M | — |
| 2024 | 2024-12-31 | −$217.1M | $33.7M | — |
| 2023 | 2023-12-31 | −$250.8M | −$841,000 | — |
| 2022 | 2022-12-31 | −$250.0M | −$419.5M | — |
| 2021 | 2021-12-31 | $169.5M | $280.4M | — |
| 2020 | 2020-12-31 | −$110.8M | $31.0M | — |
| 2019 | 2019-12-31 | −$141.8M | −$233.9M | — |
| 2018 | 2018-12-31 | $92.1M | $165.3M | — |
| 2017 | 2017-12-31 | −$73.2M | −$8.4M | — |
| 2016 | 2016-12-31 | −$64.8M | −$41.7M | — |
| 2015 | 2015-12-31 | −$23.1M | −$19.4M | — |
| 2014 | 2014-12-31 | −$3.7M | $1.1M | — |
| 2013 | 2013-12-31 | −$4.8M | — | — |
Regenxbio quarterly ebitda
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $33.0M | $92.4M | — |
| Q1 2026 | 2026-03-31 | −$79.5M | −$95.6M | — |
| Q4 2025 | 2025-12-31 | −$53.8M | −$6.4M | — |
| Q3 2025 | 2025-09-30 | −$48.5M | $9.6M | — |
| Q2 2025 | 2025-06-30 | −$59.4M | −$7.4M | — |
| Q1 2025 | 2025-03-31 | $16.1M | $75.8M | — |
| Q4 2024 | 2024-12-31 | −$47.3M | $12.2M | — |
| Q3 2024 | 2024-09-30 | −$58.1M | $2.5M | — |
| Q2 2024 | 2024-06-30 | −$52.0M | $16.7M | — |
| Q1 2024 | 2024-03-31 | −$59.7M | $2.3M | — |
| Q4 2023 | 2023-12-31 | −$59.6M | −$5.9M | — |
| Q3 2023 | 2023-09-30 | −$60.6M | $6.9M | — |
| Q2 2023 | 2023-06-30 | −$68.7M | −$8.8M | — |
| Q1 2023 | 2023-03-31 | −$62.0M | $7.0M | — |
| Q4 2022 | 2022-12-31 | −$53.6M | −$369.8M | — |
| Q3 2022 | 2022-09-30 | −$67.5M | −$13.0M | — |
| Q2 2022 | 2022-06-30 | −$59.9M | −$9.9M | — |
| Q1 2022 | 2022-03-31 | −$68.9M | −$26.8M | — |
| Q4 2021 | 2021-12-31 | $316.2M | $367.7M | — |
| Q3 2021 | 2021-09-30 | −$54.5M | −$70.6M | — |
| Q2 2021 | 2021-06-30 | −$50.0M | −$10.3M | — |
| Q1 2021 | 2021-03-31 | −$42.1M | −$6.4M | — |
| Q4 2020 | 2020-12-31 | −$51.5M | −$13.1M | — |
| Q3 2020 | 2020-09-30 | $16.1M | $50.2M | — |
| Q2 2020 | 2020-06-30 | −$39.7M | −$4.6M | — |
| Q1 2020 | 2020-03-31 | −$35.7M | −$1.4M | — |
| Q4 2019 | 2019-12-31 | −$38.4M | −$42.2M | — |
| Q3 2019 | 2019-09-30 | −$34.0M | −$12.2M | — |
| Q2 2019 | 2019-06-30 | −$35.1M | −$42.4M | — |
| Q1 2019 | 2019-03-31 | −$34.3M | −$137.2M | — |
| Q4 2018 | 2018-12-31 | $3.8M | $19.6M | — |
| Q3 2018 | 2018-09-30 | −$21.8M | −$1.2M | — |
| Q2 2018 | 2018-06-30 | $7.2M | $21.6M | — |
| Q1 2018 | 2018-03-31 | $102.9M | $125.2M | — |
| Q4 2017 | 2017-12-31 | −$15.9M | $4.3M | — |
| Q3 2017 | 2017-09-30 | −$20.6M | −$2.1M | — |
| Q2 2017 | 2017-06-30 | −$14.4M | $543,000 | — |
| Q1 2017 | 2017-03-31 | −$22.4M | −$11.2M | — |
| Q4 2016 | 2016-12-31 | −$20.2M | −$14.7M | — |
| Q3 2016 | 2016-09-30 | −$18.5M | −$11.2M | — |
| Q2 2016 | 2016-06-30 | −$14.9M | −$8.6M | — |
| Q1 2016 | 2016-03-31 | −$11.2M | −$7.2M | — |
| Q4 2015 | 2015-12-31 | −$5.5M | — | — |
| Q3 2015 | 2015-09-30 | −$7.3M | — | — |
| Q2 2015 | 2015-06-30 | −$6.3M | — | — |
| Q1 2015 | 2015-03-31 | −$4.0M | — | — |
Regenxbio ebitda trends
Over the last five fiscal years, Regenxbio's ebitda decreased from −$110.8M to −$145.6M, a change of −$34.8M. The latest reported quarter, Q2 2026, shows $33.0M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regenxbio source filings ↗Community posts
REGENXBIO reports three-year durability in diabetic-retinopathy study
REGENXBIO ($RGNX) presented three-year results from ALTITUDE, its Phase 2 study of sura-vec for diabetic retinopathy. Six of ten patients in the Dose 3 group who had reached the three-year visit showed an improvement of more than two steps ...
